GCAR1 / Alberta Health Services, Canadian Cancer Trials Group - LARVOL DELTA

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Canadian Cancer Trials Group | Trial completion date: Jun 2029 ➔ Sep 2033

Trial completion date • Alveolar Soft Tissue Sarcoma • Breast Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • GPNMB • HER-2 • PD-L1 • PGR

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Canadian Cancer Trials Group

New P1 trial • Alveolar Soft Tissue Sarcoma • Breast Cancer • Genito-urinary Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer